Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Decreased incidence, survival in low-grade serous ovarian cancer illustrate ‘diagnostic shift’

Key clinical point: The proportion of low-grade serous ovarian cancers has decreased in recent years in relation to serous borderline ovarian tumors, paralleled by a trend toward decreased survival.

Major finding: The number of low-grade serous ovarian cancers cases declined by 25.9% from 1998 to 2000, with a relative decrease of survival by 28.7% over that time period.

Study details: A retrospective, observational, population-based study including 4,712 cases of low-grade serous ovarian cancers or serous borderline ovarian tumors.

Disclosures: The study was funded by the Ensign Endowment for Gynecologic Cancer Research. The authors provided disclosures related to Chugai, Springer, VBL Therapeutics, Kiyatec, Merck, Biopath, M-Trap, Quantgene, Tesaro, GlaxoSmithKline, Celgene, Johnson & Johnson, Biogin, Clovis Oncology, Novartis, Elsevier, and UpToDate.


Matsuo K et al. Gynecol Oncol. 2020 Jan 15. doi: 10.1016/j.ygyno.2019.08.030.